In addition, our results and those of others7, 8, 9, 17 suggest that the c-Myc/IRF4 axis together with Ikaros and Aiolos may represent the so-called ‘Achilles heel' in MM, and through rational combinations of IMiD immunomodulatory drugs with targeted inhibitors of c-Myc it may be possible to explore beneficial therapeutic opportunities for patients. Here, MYC is linked to Miyoshi myopathy.